Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active therapeutic options and best supportive care (BSC) after progression to nivolumab and cabozantinib in mRCC.

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study / Roviello, Giandomenico; Gambale, Elisabetta; Giorgione, Roberta; Santini, Daniele; Stellato, Marco; Fornarini, Giuseppe; Rebuzzi, Sara Elena; Basso, Umberto; Bimbatti, Davide; Doni, Laura; Nesi, Gabriella; Bersanelli, Melissa; Buti, Sebastiano; De Giorgi, Ugo; Galli, Luca; Sbrana, Andrea; Conca, Raffaele; Carella, Claudia; Naglieri, Emanuele; Pignata, Sandro; Procopio, Giuseppe; Antonuzzo, Lorenzo. - In: CANCER MEDICINE. - ISSN 2045-7634. - STAMPA. - 11:(2022), pp. 3084-3092. [10.1002/cam4.4681]

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study

Roviello, Giandomenico;Gambale, Elisabetta;Giorgione, Roberta;Nesi, Gabriella;Antonuzzo, Lorenzo
2022

Abstract

Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active therapeutic options and best supportive care (BSC) after progression to nivolumab and cabozantinib in mRCC.
2022
CANCER MEDICINE
11
3084
3092
Roviello, Giandomenico; Gambale, Elisabetta; Giorgione, Roberta; Santini, Daniele; Stellato, Marco; Fornarini, Giuseppe; Rebuzzi, Sara Elena; Basso, Umberto; Bimbatti, Davide; Doni, Laura; Nesi, Gabriella; Bersanelli, Melissa; Buti, Sebastiano; De Giorgi, Ugo; Galli, Luca; Sbrana, Andrea; Conca, Raffaele; Carella, Claudia; Naglieri, Emanuele; Pignata, Sandro; Procopio, Giuseppe; Antonuzzo, Lorenzo
1a - Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Cancer Medicine - 2022 - Roviello - Effect of systemic therapies or best supportive care after disease progression to both.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 344.91 kB
Formato Adobe PDF
344.91 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1287002
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact